PVLA Palvella Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 4, 2026
$132,47
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$65,9352 haftanın en düşüğü
$161,3852 haftanın en yükseği
Piyasa Değeri (MRQ)
$1.91B
P/E
-35.7
Hisse Başına Kâr
$-3.71
Gelir
$43M
rozetleriniz
52 Haftlık Aralık
$66–$161
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$231
P/E
-35.7
ROE
-110.1%
Net Kâr Marjı
-1610.6%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
PVLA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$132.47
Piyasa Değeri (MRQ)
$1.91B
P/E
-35.7
Hisse Başına Kâr
$-3.71
Gelir
$43M
ROE
-110.1%
52 Haftlık Aralık
$66–$161
PVLA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 23 Nisan 2024 | 1-for-80 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$43M2017-12-31 → 2023-12-31
Hisse Başına Kâr$-3.712020-12-31 → 2025-12-31
Serbest Nakit Akışı·2017-12-31 → 2022-12-31
Net kar marjı-1610.6%2017-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | PVLA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -35.75Y ort. ≈-113.6 | ≈-113.6 | · | · | |
| P/S (F/S) | 83.85Y ort. ≈104.1 | ≈104.1 | 25.9 | Aşırı değerli | |
| F/D (MRQ) | 8.85Y ort. ≈90.1 | ≈90.1 | 5.4 | Aşırı değerli | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -65.65Y ort. ≈-55.8 | ≈-55.8 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 58.65Y ort. ≈159.6 | ≈159.6 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | PVLA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Operating Margin (Faaliyet Kâr Marjı) | -1490.4% | · | -668.2% | Ortalamanın altında | |
| EBITDA Margin (FAVÖK Marjı) | -1490.4% | · | -668.2% | Ortalamanın altında | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | -1610.6% | · | -765.9% | Zayıf | |
| Net Profit Margin (Net Kâr Marjı) | -1610.6% | · | -669.0% | Ortalamanın altında | |
| ROA | -56.5%5Y ort. ≈-39.9% | ≈-39.9% | -42.9% | Zayıf | |
| ROE | -110.1%5Y ort. ≈-20.5% | ≈-20.5% | -60.0% | Zayıf | |
| ROIC | -137.9%5Y ort. ≈-105.4% | ≈-105.4% | -62.3% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | PVLA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 21.25Y ort. ≈4.8 | ≈4.8 | 6.0 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 5.15Y ort. ≈4.6 | ≈4.6 | 4.4 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | PVLA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 65.3%5Y ort. ≈18.3% | ≈18.3% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 13.4% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | PVLA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.0 | · | 0.1 | Zayıf | |
| Receivables Turnover (Alacak Devir Hızı) | 14.5 | · | 4.6 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.5M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-53.9%
Sonraki Rapor
Kas 09, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 13, 2026 | $-1.52 | $-1.18 | -28.5% |
| 31 Mart 2026 | May 14, 2026 | $-1.20 | $-0.95 | -26.2% |
| 31 Aralık 2025 | $-1.07 | $-0.93 | -15.2% | |
| 30 Eylül 2025 | $-1.03 | $-0.86 | -20.5% | |
| 30 Haziran 2025 | $-0.86 | $-0.76 | -13.8% | |
| 31 Mart 2025 | $-0.74 | $-1.24 | 40.1% | |
| 31 Aralık 2024 | $-2.72 | $-0.66 | -313.4% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $43M | $26M | $31M | $29M | $46M | $29M | $25M | $6M | $3M | $5M | |
| R&D Expense | $23M | $8M | $9M | $53M | $67M | $47M | $55M | $41M | $22M | $20M | $8M | $6M | |
| SG&A Expense | $16M | $6M | $3M | $16M | $17M | $17M | $18M | $18M | $18M | $9M | $8M | $7M | |
| Operating Expenses | $39M | $14M | $12M | $69M | $83M | $63M | $73M | $60M | $40M | $29M | $17M | $13M | |
| Operating Income | $-39M | $-14M | $-12M | $-43M | $-52M | $-34M | $-27M | $-31M | $-15M | $-23M | $-14M | $-7M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Other Non-op | $727.0K | $-131.0K | $712.0K | $1M | $2M | $-4M | $-26.0K | $2M | $-2M | $120.0K | $10.9K | $3.0K | |
| Pretax Income | $-42M | $-17M | $19M | $-33M | $-46M | $-37M | $-25M | $-27M | $-17M | $-23M | $-14M | $-10M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $164.0K | $0 | $-312.0K | $1M | $162.0K | $203.9K | $-18 | |
| Net Income | $-42M | $-17M | $19M | $-33M | $-46M | $-37M | $-25M | $-27M | $-18M | $-23M | $-14M | $-10M | |
| EPS (Basic) | $-3.71 | $-7.83 | $2.19 | $-0.45 | $-0.71 | $-0.68 | · | · | · | · | · | · | |
| EPS (Diluted) | $-3.71 | $-7.83 | $2.17 | · | $-0.71 | $-0.68 | · | · | · | · | · | · | |
| Shares (Basic) | 11,251,250 | 2,225,934 | 1,770,167 | 74,172,000 | 64,547,000 | 54,481,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 11,251,250 | 2,225,934 | 1,793,980 | · | 64,547,000 | 54,481,000 | · | · | · | · | · | · | |
| EBITDA | $-39M | $-14M | · | $-41M | · | $-34M | $-27M | $-31M | $-15M | · | · | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $58M | $84M | $7M | $39M | $118M | $70M | $62M | $75M | $38M | $29M | $29M | $18M | |
| Short-term Investments | $0 | · | $9M | $21M | $0 | $0 | $42M | $53M | $35M | $0 | · | · | |
| Receivables | $0 | $358.0K | $0 | $6M | $3M | $2M | $7M | $3M | $16M | $57.0K | $0 | $0 | |
| Prepaid Expense | $1M | $2M | $198.0K | $3M | $7M | $4M | $4M | $5M | $2M | $3M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $59M | $88M | $8M | $73M | $128M | $76M | $115M | $135M | $90M | $33M | $32M | $20M | |
| PP&E (Net) | · | · | $0 | $17M | $19M | $22M | $20M | $5M | $4M | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | · | $27M | $27M | $28M | $23M | $8M | $7M | $5M | $4M | $4M | |
| Accum. Depreciation | · | · | · | $10M | $8M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | |
| Other Non-current Assets | · | · | $0 | $1M | $3M | $3M | $3M | $910.0K | $130.0K | $126.0K | $126.8K | · | |
| Total Assets | $60M | $88M | $8M | $95M | $154M | $105M | $141M | $141M | $104M | $35M | $34M | $22M | |
| Accounts Payable | $5M | $5M | $936.0K | $4M | $9M | $2M | $6M | $3M | $2M | $2M | $1M | · | |
| Accrued Liabilities | · | · | · | · | · | $8M | $10M | $9M | $6M | $4M | $2M | $986.6K | |
| Current Liabilities | $11M | $12M | $2M | $37M | $51M | $22M | $27M | $48M | $46M | $8M | $3M | $4M | |
| Capital Leases | $431.0K | $0 | $0 | $12M | $14M | $16M | $15M | $0 | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $6.0K | $0 | $27.0K | $37.0K | $47.0K | $23.9K | $334.0K | |
| Total Liabilities | $32M | $26M | $11M | $68M | $103M | $74M | $90M | $101M | $92M | $10M | $3M | $4M | |
| Common Stock | $12.0K | $11.0K | $0 | $74.0K | $72.0K | $56.0K | $55.0K | $54.0K | $45.0K | $43.0K | $39.8K | $29.3K | |
| Paid-in Capital | $163M | $156M | $2M | $319M | $307M | · | · | · | · | · | $112M | $85M | |
| Retained Earnings | $-135M | $-94M | $-76M | $-290M | $-257M | $-211M | $-174M | $-147M | $-120M | $-103M | $-80M | $-66M | |
| AOCI | $83.0K | $3.0K | $0 | $-254.0K | $829.0K | $-295.0K | $-2M | $-3M | $-5M | $-2M | $-1M | $-843.1K | |
| Stockholders' Equity | $28M | $63M | $-74M | $-94M | $51M | $31M | $51M | $40M | $12M | $25M | $31M | $18M | |
| Liabilities + Equity | $60M | $88M | $8M | $95M | $154M | $105M | $141M | $141M | $104M | $35M | $34M | $22M | |
| Shares Outstanding | 12,380,933 | 11,012,105 | 1,770,167 | 74,519,103 | 72,222,661 | 56,003,000 | 55,212,437 | 54,151,219 | 45,017,062 | 43,058,827 | 39,833,023 | 29,279,522 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $2M | $3M | $2M | · | · | · | · | · | · | · | |
| Stock-based Comp | $6M | $830.0K | $603.0K | $4M | $5M | $5M | $5M | $5M | $3M | $2M | $1M | $571.4K | |
| Deferred Tax | · | · | $0 | $0 | $0 | $0 | $0 | $-164.0K | $0 | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | $-34M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-25M | $-11M | $-14M | $-60M | $-8M | $-46M | $-52M | $-1M | $50M | $-14M | $-13M | $-5M | |
| CapEx | · | · | $171.0K | $1M | $949.0K | $3M | $2M | $2M | $2M | $560.0K | $620.7K | $267.4K | |
| Investing Cash Flow | · | · | $12M | $-21M | $-949.0K | $39M | $10M | $-9M | $-46M | · | · | · | |
| Stock Issued | · | · | $20M | $7M | $38M | $10M | · | · | · | · | $26M | $12M | |
| Net Stock Activity | · | · | · | $7M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-660.0K | $87M | $5M | $7M | $59M | $10M | $32M | $49M | $4M | · | · | · | |
| Net Change in Cash | $-26M | $76M | $-9M | $-79M | $47M | $8M | $-13M | $37M | $9M | $6.0K | $11M | $15M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | · | $51.7K | |
| Free Cash Flow | · | · | · | $-61M | · | $-49M | $-55M | $-3M | $48M | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1490.4% | · | · | -167.8% | · | -115.7% | -58.7% | -105.9% | -57.7% | · | · | · | |
| Net Margin | -1610.6% | · | · | -128.5% | · | -127.0% | -55.0% | -91.9% | -69.8% | · | · | · | |
| Pretax Margin | -1610.6% | · | · | -128.5% | · | -126.4% | -55.0% | -93.0% | -65.5% | · | · | · | |
| EBITDA Margin | -1490.4% | · | · | -157.1% | · | -115.7% | -58.7% | -105.9% | -57.7% | · | · | · | |
| ROA | -56.5% | -36.4% | · | -26.7% | · | -30.3% | -17.9% | -21.8% | -25.4% | · | · | · | |
| ROE | -110.1% | 140.6% | · | -92.1% | · | -99.7% | -70.8% | -59.3% | -96.0% | · | · | · | |
| ROIC | -137.9% | -22.5% | · | -155.7% | · | -109.8% | -52.9% | -76.3% | -135.1% | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 7.3 | · | 2.0 | · | 3.4 | 4.3 | 2.8 | 2.0 | · | · | · | |
| Quick Ratio | 5.1 | 7.0 | · | 1.8 | · | 3.3 | 4.1 | 2.7 | 1.9 | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | 0.2 | · | 0.2 | 0.3 | 0.2 | 0.4 | · | · | · | |
| Receivables Turnover | 14.5 | · | · | 5.7 | · | 6.9 | 9.8 | 3.2 | 3.2 | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.26 | $5.69 | · | $0.37 | · | $0.55 | $0.93 | $0.74 | $0.26 | · | · | · | |
| Revenue / Share | $0.23 | · | · | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.22 | $-4.87 | · | · | · | · | · | · | · | · | · | · | |
| Cash / Share | $4.68 | $7.59 | · | $0.52 | · | $1.26 | $1.13 | $1.38 | $0.84 | · | · | · | |
| EPS (TTM) | $-3.71 | $-7.83 | $2.17 | $-0.70 | $-0.71 | $-0.68 | · | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 65.3% | -17.6% | 7.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | · | 13.4% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20M | $20M | $43M | $26M | $31M | $29M | $46M | $29M | $25M | $6M | $3M | $5M | |
| Net Income TTM | $-42M | $-17M | $19M | $-33M | $-46M | $-37M | $-25M | $-27M | $-18M | $-23M | $-14M | $-10M | |
| Market Cap | $1.30B | $132M | · | $6.20B | · | $11.20B | $15.99B | $11.52B | $27.19B | · | · | · | |
| P/E | -28.2 | -1.5 | 6.7 | -118.9 | -425.9 | -294.1 | · | · | · | · | · | · | |
| P/S | 66.2 | 6.8 | · | 239.4 | · | 382.0 | 345.5 | 396.0 | 1075.8 | · | · | · | |
| P/B | 46.3 | 2.1 | · | 222.0 | · | 361.0 | 311.4 | 288.6 | 2359.9 | · | · | · | |
| P / Tangible Book | 46.3 | 2.1 | · | · | 430.3 | 361.0 | · | · | · | · | · | · | |
| P / Cash Flow | -51.8 | -12.2 | · | -103.5 | · | -244.0 | -304.8 | -10809.9 | 546.5 | · | · | · | |
| P / FCF | · | · | · | -101.7 | · | -230.4 | -291.1 | -4169.1 | 568.8 | · | · | · | |
| Earnings Yield | -3.5% | -65.2% | 14.9% | -0.84% | -0.23% | -0.34% | · | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | $0 | $0 | $53.0K | · | $20M | $20M | $2M | $6M | $5M | |
| R&D Expense | $12M | $9M | $7M | $7M | $5M | $4M | $3M | $3M | $1M | $984.0K | $-29M | $10M | $14M | $13M | $13M | $14M | |
| SG&A Expense | $9M | $6M | $4M | $4M | $4M | $4M | $2M | $2M | $1M | $775.0K | $-11M | $7M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $21M | $15M | $11M | $10M | $9M | $8M | $4M | $5M | $3M | $2M | $-55M | $31M | $18M | $17M | $17M | $18M | |
| Operating Income | $-21M | $-15M | $-11M | $-10M | $-9M | $-8M | $-4M | $-5M | $-3M | $-2M | $13M | $-12M | $2M | $-16M | $-12M | $-12M | |
| Other Non-op | $-8.0K | $-32.0K | $-92.0K | $34.0K | $561.0K | $224.0K | $-175.0K | $-20.0K | $64.0K | $0 | $424.0K | $506.0K | $-161.0K | $-57.0K | $-325.0K | $723.0K | |
| Pretax Income | $-22M | $-16M | $-13M | $-11M | $-9M | $-8M | $-4M | $-7M | $-4M | $-3M | · | · | · | · | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $-22M | $-16M | $-13M | $-11M | $-9M | $-8M | $-4M | $-7M | $-4M | $-3M | $39M | $-11M | $4M | $-13M | $-8M | $-10M | |
| EPS (Basic) | $-1.52 | $-1.20 | $-1.08 | $-1.03 | $-0.86 | $-0.74 | $0.12 | $-3.94 | $-2.47 | $-1.54 | $21.41 | $-8.70 | $3.63 | $-14.15 | $-0.11 | $-0.13 | |
| EPS (Diluted) | $-1.52 | $-1.20 | $-1.08 | $-1.03 | $-0.86 | $-0.74 | $0.12 | $-3.94 | $-2.47 | $-1.54 | $20.50 | $-8.70 | $3.62 | · | · | · | |
| Shares (Basic) | 14,356,219 | 13,085,271 | · | 11,064,282 | 11,052,741 | 11,013,697 | · | 1,770,167 | 1,770,167 | 1,770,167 | · | 1,236,000 | 1,095,000 | 931,000 | · | 74,397,000 | |
| Shares (Diluted) | 14,356,219 | 13,085,271 | · | 11,064,282 | 11,052,741 | 11,013,697 | · | 1,770,167 | 1,770,167 | 1,770,167 | · | 1,236,000 | 1,098,000 | · | · | · | |
| EBITDA | $-21M | $-15M | · | $-10M | $-9M | $-8M | · | $-3M | $-4M | $-5M | · | $-12M | $2M | $-15M | · | $-12M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $188M | $206M | $58M | $64M | $70M | $76M | $84M | $19M | $20M | $19M | $7M | $33M | $45M | $40M | $39M | $48M | |
| Short-term Investments | $63M | $55M | · | · | · | · | · | $0 | $0 | $0 | · | $12M | $10M | $9M | $21M | $21M | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $358.0K | $373.0K | $1M | $2M | $0 | $1M | $952.0K | $1M | $6M | $829.0K | |
| Prepaid Expense | $2M | $1M | $1M | $1M | $1M | $2M | $2M | $280.0K | $649.0K | $3M | $198.0K | $9M | $11M | $11M | $3M | $8M | |
| Current Assets | $253M | $263M | $59M | $67M | $74M | $79M | $88M | · | · | · | $8M | $59M | $66M | $61M | $73M | $79M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $0 | $16M | $17M | $17M | $16M | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | $27M | $27M | $27M | $24M | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | $11M | $10M | $10M | $8M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | · | · | · | $287.0K | $1M | $1M | $1M | $1M | |
| Total Assets | $254M | $264M | $60M | $67M | $74M | $79M | $88M | $21M | $25M | $29M | $8M | $59M | $88M | $82M | $95M | $99M | |
| Accounts Payable | $7M | $5M | $5M | $3M | $5M | $4M | $5M | $801.0K | $969.0K | $2M | $936.0K | $3M | $8M | $6M | $4M | $4M | |
| Current Liabilities | $12M | $9M | $11M | $10M | $10M | $9M | $12M | $4M | $6M | $8M | $2M | $29M | $34M | $43M | $37M | $34M | |
| Capital Leases | $318.0K | $375.0K | $431.0K | · | · | · | $0 | · | · | · | · | $0 | $12M | $12M | $12M | $11M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Total Liabilities | $37M | $31M | $32M | $28M | $26M | $24M | $26M | · | · | · | $11M | $29M | $47M | $67M | $68M | $63M | |
| Common Stock | $14.0K | $14.0K | $12.0K | $11.0K | $11.0K | $11.0K | $11.0K | $1.0K | $1.0K | $1.0K | $0 | $99.0K | $99.0K | $74.0K | $74.0K | $74.0K | |
| Paid-in Capital | $390M | $383M | $163M | $161M | $159M | $157M | $156M | $343M | $343M | $342M | $2M | $341M | $340M | $319M | $319M | $317M | |
| Retained Earnings | $-173M | $-151M | $-135M | $-123M | $-111M | $-102M | $-94M | $-326M | $-323M | $-320M | $-76M | $-310M | $-300M | $-304M | $-290M | $-282M | |
| AOCI | $89.0K | $95.0K | $83.0K | $104.0K | $-111.0K | $-3.0K | $3.0K | $-316.0K | $-436.0K | $-346.0K | $0 | $-339.0K | $-137.0K | $-426.0K | $-254.0K | $524.0K | |
| Stockholders' Equity | $217M | $232M | $28M | $39M | $48M | $56M | $63M | $16M | $19M | $22M | $-74M | $31M | $40M | $15M | $28M | $36M | |
| Liabilities + Equity | $254M | $264M | $60M | $67M | $74M | $79M | $88M | $21M | $25M | $29M | $8M | $59M | $88M | $82M | $95M | $99M | |
| Shares Outstanding | 14,395,705 | 14,313,659 | 12,380,933 | 11,088,329 | 11,059,665 | 11,021,389 | 11,012,105 | 1,320,240 | 1,320,240 | 1,236,688 | 1,770,167 | · | 98,851,927 | 74,519,103 | 74,519,103 | 74,406,253 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $0 | $0 | $-30.0K | · | $739.0K | $758.0K | $605.0K | $575.0K | $767.0K | |
| Stock-based Comp | $5M | $3M | $2M | $2M | $1M | $1M | $268.0K | $-331.0K | $-109.0K | $146.0K | $-2M | $966.0K | $1M | $884.0K | $949.0K | $974.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-7M | · | · | · | $1M | · | · | |
| Operating Cash Flow | $-13M | $-11M | $-5M | $-8M | $-5M | $-7M | $-5M | $3M | $4M | $-1M | $20M | $-10M | $-13M | $-11M | $-13M | $-9M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | · | $69.0K | $67.0K | $48.0K | $-11.0K | $34.0K | |
| Investing Cash Flow | $-7M | $-55M | · | · | $0 | $0 | · | $142.0K | $2M | $9M | · | $-2M | $-1M | $12M | $1M | $5M | |
| Stock Issued | $0 | $230M | · | · | $0 | $0 | · | $0 | · | · | · | $0 | $20M | $0 | $0 | $282.0K | |
| Net Stock Activity | · | $230M | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $1M | $215M | $-49.0K | $242.0K | $349.0K | $-1M | $75M | $12M | $10M | $0 | $-15M | $0 | $20M | $0 | $93.0K | $282.0K | |
| Net Change in Cash | $-19M | $148M | $-6M | $-7M | $-5M | $-8M | $69M | $5M | $5M | $-1M | $-3M | $-12M | $5M | $1M | $-10M | $-6M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-7M | · | · | · | $-11M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1089.3% | -1384.4% | · | -1620.5% | -1340.6% | -1046.7% | · | · | · | -10005.7% | · | -60.5% | 10.3% | -801.2% | · | -226.6% | |
| Net Margin | -1113.0% | -1469.4% | · | -1806.5% | -1372.6% | -1088.4% | · | · | · | -9230.2% | · | -55.1% | 19.8% | -680.9% | · | -181.3% | |
| Pretax Margin | -1113.0% | -1469.4% | · | -1806.5% | -1372.6% | -1088.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1089.3% | -1384.4% | · | -1620.5% | -1340.6% | -1046.7% | · | · | · | -10062.3% | · | -60.5% | 10.3% | -769.9% | · | -226.6% | |
| ROA | -13.4% | -9.2% | · | -25.9% | -19.2% | -15.0% | · | -7.2% | -6.4% | -8.8% | · | -13.6% | 3.9% | -12.0% | · | -7.4% | |
| ROE | -16.5% | -10.9% | · | -41.3% | -28.5% | -21.1% | · | -12.3% | -12.1% | -26.2% | · | -32.5% | 9.4% | -38.3% | · | -21.7% | |
| ROIC | -9.9% | -6.4% | · | -26.3% | -19.4% | -14.2% | · | · | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 21.2 | 28.9 | · | 6.5 | 7.7 | 8.8 | · | · | · | · | · | 2.0 | 1.9 | 1.4 | · | 2.3 | |
| Quick Ratio | 21.0 | 28.7 | · | 6.2 | 7.3 | 8.4 | · | 4.6 | 3.3 | 2.8 | · | 1.6 | 1.6 | 1.2 | · | 2.1 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | 0.2 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | 3.4 | 0.9 | 0.8 | · | 0.0 | 0.0 | 0.0 | · | 20.8 | 18.1 | 1.4 | · | 1.4 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $15.06 | $16.23 | · | $3.49 | $4.32 | $5.04 | · | $12.32 | $14.17 | $17.76 | · | · | $0.41 | $0.21 | · | $0.48 | |
| Revenue / Share | $0.14 | $0.08 | · | $0.06 | $0.06 | $0.07 | · | $0.00 | $0.00 | · | · | · | $0.23 | · | · | · | |
| Cash Flow / Share | · | $-0.83 | · | · | · | $-0.61 | · | · | · | · | · | · | · | · | · | · | |
| Cash / Share | $13.05 | $14.42 | · | $5.73 | $6.37 | $6.86 | · | $14.67 | $14.95 | $15.43 | · | · | $0.45 | $0.53 | · | $0.65 | |
| EPS (TTM) | $-4.83 | $-4.17 | · | $-2.51 | $-5.42 | $-7.03 | · | $12.55 | $7.79 | $13.88 | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $47M | $33M | $17M | · | $28M | |
| Net Income TTM | $-62M | $-49M | · | $-33M | $-28M | $-23M | · | $25M | $21M | $29M | · | $-28M | $-27M | $-41M | · | $-35M | |
| Market Cap | $2.20B | $1.78B | · | $695M | $249M | $308M | · | $22M | $13M | $18M | · | · | $1.31B | $5.82B | · | $6.85B | |
| P/E | -31.6 | -29.9 | · | -25.0 | -4.2 | -4.0 | · | 1.3 | 1.3 | 1.1 | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | 39.5 | 345.3 | · | 240.2 | |
| P/B | 10.1 | 7.7 | · | 18.0 | 5.2 | 5.6 | · | 1.3 | 0.7 | 0.8 | · | · | 32.4 | 376.4 | · | 191.4 | |
| P / Tangible Book | 10.1 | 7.7 | · | 18.0 | 5.2 | 5.6 | · | 1.3 | 0.7 | 0.8 | · | · | 32.4 | 376.4 | · | 191.4 | |
| P / Cash Flow | · | -164.2 | · | · | · | -45.6 | · | · | · | -2.6 | · | · | · | -529.1 | · | · | |
| Earnings Yield | -3.2% | -3.4% | · | -4.0% | -24.1% | -25.1% | · | 75.7% | 79.4% | 94.8% | · | · | · | · | · | · |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | · | · | $43M | $26M | $31M |
| Faaliyet Kâr Marjı % | -1490.4% | · | · | -167.8% | · |
| Net Gelir | $-42M | $-17M | $19M | $-33M | $-46M |
| Seyreltilmiş Hisse Başı Kâr | $-3.71 | $-7.83 | $2.17 | · | $-0.71 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 5.2 | 7.3 | · | 2.0 | · |
| Cari Oran | 5.1 | 7.0 | · | 1.8 | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | · | · | · | $-61M | · |
Kurumsal Sahipler (13F) 210 dosya · $2.2B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
210
Tutulan Değer
$2.2B
Yeni pozisyonlar
35
Çıkan pozisyonlar
19
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 35 (-35 önceki Ç'ye göre) | 19 (-3 önceki Ç'ye göre) | 93 (+24 önceki Ç'ye göre) | 45 (+15 önceki Ç'ye göre) | +820K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $173.512.745 | 1.135.406 | 7,97% | Hisse senetleri |
| JENNISON ASSOCIATES LLC | $146.801.795 | 960.619 | 6,75% | Hisse senetleri |
| BlackRock, Inc. | $140.343.317 | 918.357 | 6,45% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $134.848.368 | 882.400 | 6,20% | Hisse senetleri |
| First Light Asset Management, LLC | $117.961.911 | 771.901 | 5,42% | Hisse senetleri |
| BVF INC/IL | $102.815.615 | 672.789 | 4,72% | Hisse senetleri |
| STATE STREET CORP | $99.817.745 | 653.172 | 4,59% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $78.517.999 | 513.794 | 3,61% | Hisse senetleri |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $73.175.272 | 478.833 | 3,36% | Hisse senetleri |
| FEDERATED HERMES, INC. | $66.173.352 | 433.015 | 3,04% | Hisse senetleri |
| VANGUARD GROUP INC | $58.679.676 | 560.616 | 2,70% | Hisse senetleri |
| Woodline Partners LP | $48.522.948 | 317.517 | 2,23% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $44.678.455 | 292.360 | 2,05% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $42.213.033 | 276.164 | 1,94% | Hisse senetleri |
| Siren, L.L.C. | $39.348.858 | 257.485 | 1,81% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $39.149.734 | 256.182 | 1,80% | Hisse senetleri |
| EVENTIDE ASSET MANAGEMENT, LLC | $35.375.385 | 231.484 | 1,63% | Hisse senetleri |
| EMERALD ADVISERS, LLC | $35.070.051 | 229.486 | 1,61% | Hisse senetleri |
| FMR LLC | $32.831.927 | 214.841 | 1,51% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $31.557.391 | 253.168 | 1,45% | Hisse senetleri |
| MPM BIOIMPACT LLC | $31.179.406 | 204.027 | 1,43% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $30.795.370 | 201.514 | 1,42% | Hisse senetleri |
| MORGAN STANLEY | $27.725.827 | 181.428 | 1,27% | Hisse senetleri |
| First Turn Management, LLC | $23.908.689 | 156.450 | 1,10% | Hisse senetleri |
| Bellevue Group AG | $23.687.100 | 155.000 | 1,09% | Hisse senetleri |
| Caption Management, LLC | $21.394.800 | 140.000 | 0,98% | Satım opsiyonu |
| EMERALD MUTUAL FUND ADVISERS TRUST | $19.843.219 | 129.847 | 0,91% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $19.707.973 | 128.962 | 0,91% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.430.092 | 120.600 | 0,85% | Alım opsiyonu |
| Aberdeen Group plc | $18.374.771 | 120.238 | 0,84% | Hisse senetleri |
| NORTHERN TRUST CORP | $14.853.034 | 97.193 | 0,68% | Hisse senetleri |
| NEXTBio Capital Management LP | $13.739.893 | 89.909 | 0,63% | Hisse senetleri |
| Clio Asset Management LLC | $13.194.937 | 86.343 | 0,61% | Hisse senetleri |
| NEUBERGER BERMAN GROUP LLC | $12.700.411 | 83.107 | 0,58% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.706.012 | 76.600 | 0,54% | Satım opsiyonu |
| VANGUARD FIDUCIARY TRUST CO | $11.307.916 | 73.995 | 0,52% | Hisse senetleri |
| UBS Group AG | $11.083.424 | 72.526 | 0,51% | Hisse senetleri |
| Avidity Partners Management LP | $10.697.400 | 70.000 | 0,49% | Hisse senetleri |
| AWM Investment Company, Inc. | $10.608.153 | 69.416 | 0,49% | Hisse senetleri |
| SEVEN GRAND MANAGERS, LLC | $9.169.200 | 60.000 | 0,42% | Hisse senetleri |
| Clearbridge Investments, LLC | $9.068.458 | 59.341 | 0,42% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $8.713.159 | 69.901 | 0,40% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $8.336.942 | 54.554 | 0,38% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $8.140.721 | 53.270 | 0,37% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $7.979.038 | 52.212 | 0,37% | Hisse senetleri |
| Ensign Peak Advisors, Inc | $7.894.681 | 51.660 | 0,36% | Hisse senetleri |
| HSBC HOLDINGS PLC | $7.641.156 | 50.001 | 0,35% | Hisse senetleri |
| Nicholas Investment Partners, LP | $7.597.905 | 49.718 | 0,35% | Hisse senetleri |
| Balyasny Asset Management L.P. | $6.805.992 | 44.536 | 0,31% | Hisse senetleri |
| Lisanti Capital Growth, LLC | $6.567.440 | 42.975 | 0,30% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Kaupinen Wes, Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019, Christine L. Kaupinen, Christine L. Kaupinen 2019 Irrevocable Trust dated February 28, 2019, Michael Christopher | 20 Aralık 2024 | 14,60% | İlk başvuru | · | SEC |
| Biotechnology Value Fund, L.P., BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., Mark N. Lampert ×2 başvurular | 17 Ağustos 2023 | · | İlk başvuru | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC ×10 başvurular | 27 Eylül 2018 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 34 içeriden öğrenenler · 16 yöneticiler · 19 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Kaupinen Wes | President and CEO | 05 Şubat 2026 A | · | 0 | 0 | $0 |
| Stephen S. Yoder | Chief Executive Officer | 24 Şubat 2023 A | 6.000 | 0 | 0 | $0 |
| Matthew E Korenberg | CFO, Treasurer | 12 Haziran 2026 M | 1.000 | 0 | 0 | $0 |
| Thomas Bures | Chief Financial Officer | 24 Şubat 2023 A | · | 0 | 0 | $0 |
| Allan Reine | Chief Financial Officer | 26 Şubat 2019 A | 65.000 | 0 | 0 | $0 |
| Darlene M Deptula-Hicks | SVP, Chief Financial Officer | 13 Haziran 2016 P | 5.000 | 0 | 0 | $0 |
| Kathleen Goin | Chief Operating Officer | 16 Eylül 2026 M | 0 | 0 | 33 | $-5.506.479 |
| Ashley Hartmann Kline | Chief Commercial Officer | 05 Şubat 2026 A | · | 0 | 0 | $0 |
| Jeffrey S Martini | Chief Scientific Officer | 05 Şubat 2026 A | · | 0 | 0 | $0 |
| PALVELLA THERAPEUTICS, INC. | Chief Scientific Officer | 05 Şubat 2025 A | · | 0 | 0 | $0 |
| Ahmed Mousa | Chief Business Officer | 24 Şubat 2023 A | · | 0 | 0 | $0 |
| Shane Olwill | Chief Development Officer | 24 Şubat 2023 A | 4.638 | 0 | 0 | $0 |
| Hitto Kaufmann | Chief Scientific Officer | 24 Şubat 2023 A | · | 0 | 0 | $0 |
| Tim Demuth | Chief Medical Officer | 13 Mayıs 2022 P | 6.000 | 0 | 0 | $0 |
| Louis Matis | Chief Development Officer | 26 Şubat 2019 A | 10.000 | 0 | 0 | $0 |
| Claude Knopf | Chief Business Officer | 28 Kasım 2016 A | · | 0 | 0 | $0 |
| George M Jenkins | Yönetim kurulu üyesi | 15 Eylül 2026 S | 160.116 | 2 | 9 | $-3.617.215 |
| Christopher P Kiritsy | Yönetim kurulu üyesi | 02 Eylül 2026 M | 250 | 0 | 1 | $-49.141 |
| Matthew Pauls | Yönetim kurulu üyesi | 29 Haziran 2026 A | · | 0 | 0 | $0 |
| Tadd S. Wessel | Yönetim kurulu üyesi | 10 Haziran 2026 A | · | 0 | 0 | $0 |
| John Doux | Yönetim kurulu üyesi | 10 Haziran 2026 A | · | 0 | 0 | $0 |
| Todd C Davis | Yönetim kurulu üyesi | 10 Haziran 2026 A | · | 0 | 0 | $0 |
| Elaine J Heron | Yönetim kurulu üyesi | 10 Haziran 2026 A | 47.812 | 1 | 0 | $300.000 |
| James A Geraghty | Yönetim kurulu üyesi | 12 Aralık 2024 D | 0 | 0 | 0 | $0 |
| Maya R. Said | Yönetim kurulu üyesi | 21 Haziran 2023 A | · | 0 | 0 | $0 |
| Ann Barbier | Yönetim kurulu üyesi | 21 Haziran 2023 A | · | 0 | 0 | $0 |
| Michael Richman | Yönetim kurulu üyesi | 21 Haziran 2023 A | · | 0 | 0 | $0 |
| Peter A Kiener | Yönetim kurulu üyesi | 21 Haziran 2023 A | · | 0 | 0 | $0 |
| Matthew L Sherman | Yönetim kurulu üyesi | 21 Haziran 2023 A | · | 0 | 0 | $0 |
| Jean-Pierre Bizzari | Yönetim kurulu üyesi | 25 Ocak 2020 A | · | 0 | 0 | $0 |
| Steven Prelack | Yönetim kurulu üyesi | 25 Ocak 2019 A | · | 0 | 0 | $0 |
| Julian Adams | Yönetim kurulu üyesi | 25 Ocak 2018 A | · | 0 | 0 | $0 |
| Chau Quang Khuong | Yönetim kurulu üyesi | 25 Ekim 2017 A | 65.398 | 0 | 0 | $0 |
| Aquilo Capital Management, LLC | 10% sahip | 21 Temmuz 2020 S | 3.675.530 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 23 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| PTH · Invesco Exchange-Traded Fund Trust | 1,13% | 24.487 SH | 02 Ekim 2026 | Günlük |
| BBC · ETFis Series Trust I | 0,86% | 2.856 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,74% | 22.508 SH | 02 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,39% | 13.887 NS | 31 Temmuz 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,18% | 22.955 SH | 19 Ağustos 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,11% | 190 NS | 31 Temmuz 2026 | N-PORT |
| IWO · iShares Trust | 0,11% | 103.168 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,10% | 11.762 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,05% | 280.820 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,05% | 63.184 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,05% | 5.240 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,02% | 1.583 SH | 11 Eylül 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 4.864 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 113.556 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,02% | 30.157 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,02% | 674 SH | 10 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 3.420 SH | 03 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 14.740 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,00% | 218 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 388.390 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 904 SH | 19 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 450 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 1.075 SH | 11 Eylül 2026 | Günlük |
PVLA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 22 analist
AL
Medyan hedef
$232.00
+75,1%
6 27,3%
Güçlü Al
15 68,2%
Al
1 4,5%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
15 analist · 2026-09-28Ortalama hedef $230.53 +74,0%
← Tüm hedeflerin altında
Mevcut fiyat $132.47
Düşük$205.00
Ortalama$230.53
Yüksek$270.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| GENB | · | · | · | · | · | · |
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | · |
| NVAX | $1.09B | 2.6 | 64.7% | 39.2% | -977.1% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 4, 2026